… pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models
… of normal or hyperplasic prostate, primary prostate tumors, lymph-nodes metastases, and
bone metastatic lesions. We observed that all primary prostate cancers expressed CXCR4, …
bone metastatic lesions. We observed that all primary prostate cancers expressed CXCR4, …
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models
G Liu, SA Taylor, CH Marrinan, Y Hsieh… - … journal of cancer, 2009 - Wiley Online Library
… prostate cancer models including PC3, DU-145, LNCaP and 22Rv1 cells.31-35 We report
here that in the prostate cancer models … Interesting in these prostate cancer models, lonafanib …
here that in the prostate cancer models … Interesting in these prostate cancer models, lonafanib …
Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model
T Satoh, T Saika, S Ebara, N Kusaka, TL Timme… - Cancer Research, 2003 - AACR
… To evaluate potential antimetastatic effects of AdmIL-12-transduced macrophages in this
prostate cancer model, we counted the number of macroscopic lung metastases on day 21 after …
prostate cancer model, we counted the number of macroscopic lung metastases on day 21 after …
High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer
K Fizazi, CR Sikes, J Kim, J Yang… - Anticancer …, 2004 - ar.iiarjournals.org
… from one preclinical study suggested synergism between docetaxel and estramustine (6),
our results, obtained with both in vivo and in vitro models employing three prostate cancer cell …
our results, obtained with both in vivo and in vitro models employing three prostate cancer cell …
[HTML][HTML] Preclinical assessment of the combination of PSMA-targeting radionuclide therapy with PARP inhibitors for prostate cancer treatment
EAM Ruigrok, NS Verkaik, E de Blois… - International Journal of …, 2022 - mdpi.com
… cancer cell killing both in vitro and in vivo [14,15,16]. Based on these preclinical successes
with NET models, … to the preclinical studies combining TRT with PARPi in NET models, to the …
with NET models, … to the preclinical studies combining TRT with PARPi in NET models, to the …
Prostate cancer chemoprevention by sulforaphane in a preclinical mouse model is associated with inhibition of fatty acid metabolism
… In conclusion, the present study demonstrates that prostate cancer prevention by SFN in a
preclinical mouse model is associated with suppression of fatty acid synthesis and possibly …
preclinical mouse model is associated with suppression of fatty acid synthesis and possibly …
Targeting the α receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis
MR Russell, Q Liu, A Fatatis - Clinical Cancer Research, 2010 - AACR
… ) is highly expressed in primary prostate cancer and associated skeletal metastases. Here, …
used a preclinical animal model of metastasis in which PC3-ML human prostate cancer cells …
used a preclinical animal model of metastasis in which PC3-ML human prostate cancer cells …
[HTML][HTML] Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer
J Kalmuk, M Folaron, J Buchinger, R Pili, M Seshadri - Oncotarget, 2015 - ncbi.nlm.nih.gov
… in preclinical models to better inform future clinical trial design [31]. In this regard, non-invasive
imaging methods can enable determination of the kinetics of tumor response or regrowth …
imaging methods can enable determination of the kinetics of tumor response or regrowth …
Studies with ZD1839 in preclinical models
FM Sirotnak - Seminars in oncology, 2003 - Elsevier
… Treatment with ZD1839 alone inhibited the growth of LX-1, a lung cancer model with a
low level of EGFR expression, and PC-3, a prostate cancer model with moderate EGFR …
low level of EGFR expression, and PC-3, a prostate cancer model with moderate EGFR …
Preclinical models of prostate cancer.
R Royai, PH Lange, R Vessella - Seminars in oncology, 1996 - europepmc.org
… , and the human cancer is unusually hard to grow in culture or as xenografts even short-term.
The prostate cancer models that do exist are basically rodent models, human cell lines, …
The prostate cancer models that do exist are basically rodent models, human cell lines, …